These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2865112)

  • 61. Liquid chromatographic determination of sulindac and metabolites in serum.
    Clark CR; McMillian CL; Hoke JF; Campagna KD; Ravis WR
    J Chromatogr Sci; 1987 Jun; 25(6):247-51. PubMed ID: 3611280
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Analytical methods for the determination of sulindac and metabolites in plasma, urine, bile, and gastric fluid by liquid chromatography using ultraviolet detection.
    Musson DG; Vincek WC; Constanzer ML; Detty TE
    J Pharm Sci; 1984 Sep; 73(9):1270-3. PubMed ID: 6491950
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of cefpiramide in rats with obstructive jaundice.
    Kimura T; Yamao T; Nakayama S; Honge S; Kawakami T; Kurosaki Y; Nakayama T
    J Pharmacobiodyn; 1988 Dec; 11(12):839-48. PubMed ID: 3254982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Excretion patterns of 125I-radioiodohippuric acid in normal and in chronically uremic rats.
    Tse JW; Shysh A; Wiebe LI
    Int J Nucl Med Biol; 1978; 5(2-3):77-82. PubMed ID: 752658
    [No Abstract]   [Full Text] [Related]  

  • 65. High-performance liquid chromatography of sulindac and its sulphone and sulphide metabolites in plasma.
    Grgurinovich N
    J Chromatogr; 1987 Feb; 414(1):211-6. PubMed ID: 3571386
    [No Abstract]   [Full Text] [Related]  

  • 66. Usefulness of Optimized Human Fecal Material in Simulating the Bacterial Degradation of Sulindac and Sulfinpyrazone in the Lower Intestine.
    Kostantini C; Arora S; Söderlind E; Ceulemans J; Reppas C; Vertzoni M
    Mol Pharm; 2022 Jul; 19(7):2542-2548. PubMed ID: 35729720
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of sulindac in ESRD.
    Diskin CJ; Ravis W; Campagna KD; Clark CR
    Nephron; 1988; 50(4):397. PubMed ID: 3237288
    [No Abstract]   [Full Text] [Related]  

  • 68. Studies on absorption, biotransformation and excretion of drug. II. Metabolism of 2-indanamine.
    Irino O; Tateishi M; Miura C; Fukawa K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):734-40. PubMed ID: 5057393
    [No Abstract]   [Full Text] [Related]  

  • 69. Determination of sulindac and its metabolites in serum by high-performance liquid chromatography.
    Dusci LJ; Hackett LP
    J Chromatogr; 1979 Apr; 171():490-3. PubMed ID: 546862
    [No Abstract]   [Full Text] [Related]  

  • 70. Computerized mass spectrometric assay for sulindac and its metabolites in human plasma.
    Walker RW; Gruber VF; Rosenberg A; Wolf FJ; VandenHeuvel WJ
    Anal Biochem; 1979 Jun; 95(2):579-86. PubMed ID: 453542
    [No Abstract]   [Full Text] [Related]  

  • 71. Granulocytosis and a sulindac overdose.
    Gross GE
    Ann Intern Med; 1982 Jun; 96(6 Pt 1):793-4. PubMed ID: 7091952
    [No Abstract]   [Full Text] [Related]  

  • 72. Sex differences in dehydroepiandrosterone metabolism in rodents.
    Hobe G; Schön R; Undisz K; Blei L; Hillesheim HG
    Ann N Y Acad Sci; 1995 Dec; 774():308-11. PubMed ID: 8597473
    [No Abstract]   [Full Text] [Related]  

  • 73. [Preclinical possibilities of evaluating nonrenal elimination of drugs].
    Bohdanecká M; Schück O; Reitschlägerová V
    Cesk Fysiol; 1990; 39(1):41-5. PubMed ID: 2350796
    [No Abstract]   [Full Text] [Related]  

  • 74. Clinical pharmacokinetics of sulindac. A dynamic old drug.
    Davies NM; Watson MS
    Clin Pharmacokinet; 1997 Jun; 32(6):437-59. PubMed ID: 9195115
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dibromosulphophthalein: its pharmacokinetics and binding to hepatic cytosol proteins in rats with acute renal failure.
    Silberstein DJ; Bowmer CJ; Yates MS
    Br J Pharmacol; 1988 Oct; 95(2):343-52. PubMed ID: 3228667
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biliary secretion of sulindac and metabolites in man.
    Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE
    Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Renal metabolism of sulindac: functional implications.
    Miller MJ; Bednar MM; McGiff JC
    J Pharmacol Exp Ther; 1984 Nov; 231(2):449-56. PubMed ID: 6436473
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of dimethyl sulfoxide on sulindac disposition in rats.
    Swanson BN; Mojaverian P; Boppana VK; Dudash MR
    Drug Metab Dispos; 1981; 9(6):499-502. PubMed ID: 6120805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.